Literature DB >> 26362764

What Constitutes an "Adequate" Trial in Migraine Prevention?

Jonathan H Smith1, Todd J Schwedt2.   

Abstract

Comprehensively assessing the quality of prior preventive treatment attempts often reveals modifiable variables that may account for treatment failure. Similarly, a comprehensive and systematic approach when planning a preventive medication trial is critical for optimizing the chances of treatment success. In this review, we summarize the key elements to be included when assessing the adequacy of a preventive treatment trial. We have developed and included checklists that can be used by providers to improve their assessments of prior preventive treatment trials and to assist with planning a high-quality treatment trial with a new migraine preventive medication.

Entities:  

Keywords:  Clinical trial; Migraine; Outcome; Prevention; Quality

Mesh:

Year:  2015        PMID: 26362764     DOI: 10.1007/s11916-015-0525-9

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  30 in total

1.  Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  S D Silberstein
Journal:  Neurology       Date:  2000-09-26       Impact factor: 9.910

2.  Migraine mimics.

Authors:  Randolph W Evans
Journal:  Headache       Date:  2015-02-06       Impact factor: 5.887

3.  A comparison between prospective Internet-based and paper diary recordings of headache among adolescents in the general population.

Authors:  Anne-Berit Krogh; Bo Larsson; Øyvind Salvesen; Mattias Linde
Journal:  Cephalalgia       Date:  2015-06-19       Impact factor: 6.292

Review 4.  Refractory migraine - a review.

Authors:  Elliott Schulman
Journal:  Headache       Date:  2013-02-13       Impact factor: 5.887

5.  Guidelines for trials of behavioral treatments for recurrent headache, first edition: American Headache Society Behavioral Clinical Trials Workgroup.

Authors:  Donald B Penzien; Frank Andrasik; Brian M Freidenberg; Timothy T Houle; Alvin E Lake; Gay L Lipchik; Kenneth A Holroyd; Richard B Lipton; Douglas C McCrory; Justin M Nash; Robert A Nicholson; Scott W Powers; Jeanetta C Rains; David A Wittrock
Journal:  Headache       Date:  2005-05       Impact factor: 5.887

6.  Canadian Headache Society guideline for migraine prophylaxis.

Authors:  Tamara Pringsheim; W Jeptha Davenport; Gordon Mackie; Irene Worthington; Michel Aubé; Suzanne N Christie; Jonathan Gladstone; Werner J Becker
Journal:  Can J Neurol Sci       Date:  2012-03       Impact factor: 2.104

7.  Management of medication overuse headache: 1-year randomized multicentre open-label trial.

Authors:  K Hagen; C Albretsen; S T Vilming; R Salvesen; M Grønning; G Helde; G Gravdahl; J-A Zwart; L J Stovner
Journal:  Cephalalgia       Date:  2008-09-24       Impact factor: 6.292

8.  Adherence to oral migraine-preventive medications among patients with chronic migraine.

Authors:  Zsolt Hepp; David W Dodick; Sepideh F Varon; Patrick Gillard; Ryan N Hansen; Emily B Devine
Journal:  Cephalalgia       Date:  2014-08-27       Impact factor: 6.292

9.  Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors:  H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal:  Cephalalgia       Date:  2007-04-18       Impact factor: 6.292

Review 10.  Chronic migraine.

Authors:  Todd J Schwedt
Journal:  BMJ       Date:  2014-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.